Business Context and Reporting Period
SelectQuote, Inc. (SLQT) is a technology-enabled, direct-to-consumer distribution platform for insurance policies and healthcare services. This Form 10-Q covers the quarterly period ended December 31, 2024 (Q2 of fiscal year 2025). The Company operates three reportable segments: Senior (Medicare-related products), Healthcare Services (primarily SelectRx pharmacy), and Life (term and final expense insurance). The Auto & Home business is now reported within an "All Other" category.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Total Revenue | $481.1 million | $773.3 million |
| Net Income | $53.2 million | $8.7 million |
| Income from Operations | $70.9 million | $59.0 million |
| Adjusted Segment EBITDA | $110.2 million | $128.7 million |
| Cash and Cash Equivalents | $12.1 million | $13.6 million (including restricted cash) |
| Total Debt (Gross) | $711.9 million | $711.9 million |
| Net Cash Used in Operating Activities | N/A | $(45.3) million |
Note: Net income for the six-month period was significantly impacted by a $7.6 million non-cash loss related to the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% year-over-year (YoY) for the quarter and 21% for the six-month period. This was driven primarily by a 65% increase in Pharmacy revenue ($180.0 million for the quarter) due to a 54% increase in SelectRx members.
- Segment Performance:
- Senior: Revenue increased 3% YoY for the quarter, driven by a 5% increase in approved policies.
- Healthcare Services: Revenue surged 64% YoY for the quarter, almost entirely due to SelectRx growth.
- Life: Revenue increased 7% YoY for the quarter, led by a 12% increase in final expense commissions.
- All Other: Revenue decreased 60% YoY for the quarter as the Company strategically reduced Auto & Home growth.
- Profitability: Operating margin improved to 15% for the quarter (from 14% prior year) and 8% for the six-month period (from 5% prior year). Adjusted EBITDA for the Senior segment increased 28% YoY for the quarter.
- Expenses: Marketing and advertising expenses decreased 17% YoY for the quarter due to improved close rates. However, Selling, General, and Administrative (SG&A) expenses increased 35% YoY, driven by compensation costs related to SelectRx growth and corporate development costs for securitization.
Guidance, Outlook, and Risks
- Capital Structure Changes: On October 15, 2024, the Company completed a $100 million securitization transaction (Class A and B Notes) and amended its Senior Secured Credit Facility (Eleventh Amendment) to extend maturities and modify covenants. This resulted in the issuance of 5.6 million warrants to lenders, classified as a liability.
- Subsequent Event (Feb 2025): The Company entered into agreements to raise $350 million in Senior Preferred Stock and warrants from Morgan Stanley and Bain Capital. Proceeds are intended to pay down $260 million of term loans and fund operations. This transaction is expected to close on February 28, 2025.
- Liquidity Concerns: Management stated it does not expect to generate sufficient cash flows from operations to make remaining milestone payments under the Eleventh Amendment without additional financing. Failure to secure capital or meet covenants could lead to default.
- Legal Proceedings: The Company is defending a consolidated securities class action lawsuit and a stockholder derivative suit. No liability has been accrued as the outcome is not currently deemed probable.
- Valuation Allowance: The Company recorded a valuation allowance of $18.7 million for deferred tax assets, resulting in a negative effective tax rate for the six-month period.
Investor Verification Checklist
- Debt Covenants: Verify the Company's ability to meet the asset coverage and minimum liquidity covenants under the amended Senior Secured Credit Facility, particularly given the reliance on the upcoming $350 million preferred stock issuance.
- Warrant Liability Volatility: Monitor the fair value of the $16.3 million warrant liability, as changes in stock price and volatility directly impact net income (resulting in a $7.6 million loss in this period).
- Operating Cash Flow: Assess the sustainability of negative operating cash flows ($45.3 million used in six months) driven by the buildup of commissions receivable and working capital needs for SelectRx expansion.
- Preferred Stock Closing: Confirm the closing of the February 28, 2025, Senior Preferred Stock transaction, which is critical for debt reduction and liquidity.
- Legal Exposure: Track the status of the consolidated securities class action litigation, specifically the motion to dismiss the second amended complaint.